DGAP-Adhoc: 4SC AG: Dr Thomas Werner and Klaus Kühn announce resignation from Supervisory Board

| Source: EQS Group AG
4SC AG  / Key word(s): Change of Personnel

18.08.2014 17:54

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


4SC AG: Dr Thomas Werner and Klaus Kühn announce resignation from
Supervisory Board

Planegg-Martinsried, 18 August 2014 - 4SC AG (Frankfurt, Prime Standard:
VSC) announces that Dr Thomas Werner and Klaus Kühn have informed the
company today that they will resign from their positions as members of the
Supervisory Board of 4SC AG for personal reasons effective at the end of 18
September 2014. Dr Werner has been a member of 4SC's Supervisory Board
since June 2009, serving as its Chairman since June 2012; Mr Kühn has been
a member of the Supervisory Board since August 2012.

The remaining Supervisory Board consisting of four members remains fully
quorate. 4SC will provide timely information about how the vacant positions
will be filled.

The Management Board of 4SC AG thanks Dr Werner and Mr Kühn for their
commendable service and their strong dedication to the company.


Information and Explaination of the Issuer to this News:

Enno Spillner, Chief Executive Officer of 4SC AG, comments: 'On behalf of
the 4SC Management Board, I wish to thank Dr Werner and Mr Kühn for their
great dedication to 4SC and for their collaboration in the past years,
which was always fair, positive and constructive. We regret their departure
very much. We will now work with our full dedication to promptly find
competent and experienced successor candidates from our industry-wide
network, whom we will nominate for replacement in accordance with the
regulatory framework.'

About 4SC 

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
targeted, small-molecule drugs for treating diseases with high unmet
medical needs in various cancer and autoimmune indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company's pipeline comprises promising products that are in
various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount
of 65 employees (55 FTEs) at 30 June 2014. 4SC AG has been listed on the
Prime Standard of the Frankfurt Stock Exchange since December 2005.

Cautionary statement regarding forward-looking statements 

This press release contains certain forward-looking statements. Any
forward-looking statement applies only on the date of this press release.
By their nature, forward-looking statements are subject to a number of
known and unknown risks and uncertainties that may or may not occur in the
future and as a result of which the actual results and performance may
differ substantially from the expected future results or performance
expressed or implied in the forward looking statements. No warranties or
representations are made as to the accuracy, achievement or reasonableness
of such statements, estimates or projections, and 4SC AG has no obligation
to update any such information or to correct any inaccuracies herein or
omission herefrom which may become apparent.

For more information please visit www.4sc.com or contact:

Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-6366

MC Services 
Katja Arnold, Michelle Kremer
katja.arnold(at)mc-services.eu, Tel.: +49-89-2102-2840

The Trout Group 
Chad Rubin
crubin(at)troutgroup.com, Tel.: +1-646-378-2947

18.08.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:     English
Company:      4SC AG
              Am Klopferspitz 19a
              82152 Martinsried
Phone:        +49 (0)89 7007 63-0
Fax:          +49 (0)89 7007 63-29
E-mail:       public@4sc.com
Internet:     www.4sc.de
ISIN:         DE0005753818
WKN:          575381
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, München, Stuttgart
End of Announcement                             DGAP News-Service